Products Baricitinib was approved in many countries and in the EU in 2017 and in the United States in 2018 in film-coated tablet form (Olumiant). Structure and properties Baricitinib (C16H17N7O2S, Mr = 371.4 g/mol) is structurally related to adenosine triphosphate and interacts with the ATP-binding site of kinases. It is sparingly soluble in water. Effects … Baricitinib
Products Pibrentasvir was approved in the United States, many countries, and the EU in 2017 as a fixed-dose combination with glecaprevir in film-coated tablet form (Maviret). Structure and properties Pibrentasvir (C57H65F5N10O8, Mr = 1113.2 g/mol) exists as a white to slightly yellow crystalline powder. Effects Pibrentasvir has antiviral properties. The effects are due to binding … Pibrentasvir
Products Niraparib was approved in the US and EU in 2017 and in many countries in 2018 in hard capsule form (Zejula). Structure and properties Niraparib (C19H20N4O, Mr = 320.4 g/mol) is present in the drug as niraparibtosilate monohydrate. It is a piperidine, indazole, and carboxamide derivative. Effects Niraparib (ATC L01XX54) has antitumor and cytotoxic … Niraparib
Products Apixaban has been approved in many countries since 2011 in the form of film-coated tablets (Eliquis). Structure and properties Apixaban (C25H25N5O4, Mr = 460.0 g/mol) was developed starting from razaxaban. It is an oxopiperidine and pyrazole derivative. Effects Apixaban (ATC B01AF02) has antithrombotic properties. It is an oral, direct, potent, selective, and reversible inhibitor … Apixaban
Products Velpatasvir was approved in 2016 in fixed combination with the HCV polymerase inhibitor sofosbuvir in film-coated tablet form (Epclusa, Gilead). Another fixed combination is Vosevi with sofosbuvir and voxilaprevir. Structure and properties Velpatasvir (C49H54N8O8, Mr = 883.0 g/mol) Effects Velpatasvir has antiviral properties. The effects are due to binding to the viral protein NS5A … Velpatasvir
Products Venetoclax was approved in the US and EU in 2016 and in many countries in 2018 in film-coated tablet form (Venclyxto, Venclexta). Structure and properties Venetoclax (C45H50ClN7O7S, Mr = 868.4 g/mol) exists as a light to dark yellow powder that is sparingly soluble in water. Effects Venetoclax (ATC L01XX52) has antitumor and cytotoxic properties. … Venetoclax
Products Talazoparib is commercially available in hard capsule form (Talzenna). It was approved in the United States in 2018 and in the EU and many countries in 2019. Structure and properties Talazoparib exists in the drug as talazoparib tosilate, a white to yellow solid. Fluorination of the drug prevents oxidative metabolism. Effects Talazoparib (ATC L01XX60) … Talazoparib
Products Rosuvastatin is commercially available in the form of film-coated tablets (Crestor, generic, auto-generic). It was approved in many countries in 2006 (Netherlands: 2002, EU and US: 2003). The marketing authorization holder is AstraZeneca. The statin was originally developed at Shionogi in Japan. In the USA, generic versions came on the market in 2016. In … Rosuvastatin
Products Rucaparib was approved in tablet form in the United States in 2016, in the EU in 2018, and in many countries in 2020 (Rubraca). Structure and properties Rucaparib (C19H18FN3O, Mr = 323.4 g/mol) is present in the drug as rucaparibcamsylate, a white to slightly yellow powder. Effects Rucaparib has antitumor and cytotoxic properties. The … Rucaparib
Products Voxilaprevir is commercially available as film-coated tablets in fixed combination with sofosbuvir and velpatasvir (Vosevi). It was approved in the United States, many countries, and the EU in 2017. Structure and properties Voxilaprevir (C40H52F4N6O9S, Mr = 868.9 g/mol) Effects Voxilaprevir has antiviral properties. The effects are due to noncovalent and reversible inhibition of the … Voxilaprevir
Products Teriflunomide is commercially available in the form of film-coated tablets (Aubagio). It was approved in many countries in 2013. Teriflunomide can be taken perorally, unlike earlier MS medications, and does not need to be injected. Structure and properties Teriflunomide (C12H9F3N2O2, Mr = 270.2 g/mol) is the active metabolite of the prodrug leflunomide (Arava), which … Teriflunomide
Products Rimegepant was approved in the United States in 2020 in the form of meltable tablets that disintegrate in the oral cavity (Nurtec ODT). ODT stands for Orally Disintegrating Tablets. Structure and properties Rimegepant exists in the drug as rimegepant sulfate (hemisulfate and sesquihydrate), a white crystalline solid that is sparingly soluble in water. Effects … Rimegepant
